Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
. These results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“EVs derived from a variety of tumor types including melanoma, glioblastoma, breast, and head and neck cancer contain functional PD-L1 on their surface (Chen et al., 2018; Ricklefs et al., 2018; Theodoraki et al., 2018).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ricklefs et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“One of themost prominent molecules used by tumor cells to engage T cell immune checkpoints is programmed death ligand 1 (PD-L1) (9, 10).”
BackgroundSelf-citationSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Cited by
Items 101–200 of 632
Pietrowska, M., Zebrowska, A., Gawin, M., Marczak, Ł., Sharma, P., Mondal, S. K., Mika, J., Polańska, J., Ferrone, S., Kirkwood, J. M., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12063 · Cited by 87
Glioblastoma Microenvironment and Cellular Interactions
Crivii, C.-B., Boșca, A. B., Melincovici, C. S., Constantin, A.-M., Mărginean, M., Dronca, E., Suflețel, R., Gonciar, D., Bungărdean, M., & Șovrea, A. (2022) · Cancers · doi:10.3390/cancers14041092 · Cited by 81
“By preventing T-cell infiltration, the growth and invasiveness of GBM are supported [35].”
BackgroundZhong, W., Lu, Y., Han, X., Yang, J., Qin, Z., Zhang, W., Yu, Z., Wu, B., Liu, S., Xu, W., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113224 · Cited by 95
Mitchell, K., Troike, K. M., Silver, D. J., & Lathia, J. D. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa259 · Cited by 96
Extracellular Vesicles as Drug Transporters
Nowak, M., Górczyńska, J., Kołodzińska, K., Rubin, J., & Choromańska, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210267 · Cited by 89
“For example, in glioblastoma (GBM) patients, the levels of PD-L1 DNA in serumand plasma-derived EVs correlated with tumor volume [62].”
BackgroundTumor-Derived Exosomes in Tumor-Induced Immune Suppression
Hao, Q., Wu, Y., Wu, Y., Wang, P., & Vadgama, J. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031461 · Cited by 85
“showed that glioblastoma TEX blocked T-cell activation and proliferation possibly through the binding of PD-L1 expressed on the surface of glioblastoma-derived TEX to the PD1 receptors on T cells [87].”
BackgroundExtracellular Vesicles in Cancer Metastasis: Potential as Therapeutic Targets and Materials
Kogure, A., Yoshioka, Y., & Ochiya, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124463 · Cited by 86
“revealed that cancer-derived EVs suppress T cell activity [45].”
BackgroundWu, J., Lin, Z., Zou, Z., Liang, S., Wu, M., Hu, Y., & Zhang, Y. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10042 · Cited by 81
Revolutionizing anti-tumor therapy: unleashing the potential of B cell-derived exosomes
Xiong, J., Chi, H., Yang, G., Zhao, S., Zhang, J., Tran, L. J., Xia, Z., Yang, F., & Tian, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188760 · Cited by 86
“Franz L and colleagues conducted a PD-1 blockade experiment using EV secreted by glioblastoma, which almost reactivated T cells and suppressed tumor progression (102).”
MethodThe Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
Tang, Y., Zhang, P., Wang, Y., Wang, J., Su, M., Wang, Y., Zhou, L., Zhou, J., Xiong, W., Zeng, Z., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00604 · Cited by 87
WJMSC‐derived small extracellular vesicle enhance T cell suppression through PD‐L1
Li, M., Soder, R. P., Abhyankar, S., Abdelhakim, H., Braun, M. W., Trinidad, C. V., Pathak, H. B., Pessetto, Z. Y., Deighan, C., Ganguly, S., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12067 · Cited by 83
“Consistent to previous studies (Chen et al., 2016; Fujii et al., 2018), our studies support that sEVs’ functions, exerted on the TCRs, primarily rely on indirectly modulatory regulation rather than the direct antigen presentation.”
BackgroundResultInfluentialDave, K. M., Pinky, P. P., & Manickam, D. S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114068 · Cited by 84
Sheehan, C. S., & D’Souza‐Schorey, C. (2019) · Journal of Cell Science · doi:10.1242/jcs.235085 · Cited by 81
Extracellular vesicles for the treatment of central nervous system diseases
Gratpain, V., Mwema, A., Labrak, Y., Muccioli, G. G., Pesch, V. V., & Rieux, A. D. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.006 · Cited by 82
Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives
Raimondo, S., Pucci, M., Alessandro, R., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072286 · Cited by 80
“Gliobastoma PD-L1 CD4+ and CD8+ Cell activation and proliferation inhibition [63]”
BackgroundYou, L., Zhao, Y., Kuča, K., Wang, X., Olekšák, P., Chrienová, Ž., Nepovimová, E., Jacevic, V. M., Wu, Q., & Wu, W. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03030-2 · Cited by 81
“With regard to other mycotoxins, such as aflatoxins and fumonisins, aflatoxin is considered to be carcinogenic to humans (Rushing and Selim 2019), and cancer is related to hypoxia (Heddleston et al.”
BackgroundYang, Q., Chen, M., Gu, J., Niu, K., Zhao, X., Zheng, L., Xu, Z., Yu, Y., Li, F., Meng, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.665133 · Cited by 83
“Not surprisingly, the PD-L1 protein was found on the surface of tumor-derived exosomes (32).”
BackgroundCurvature-sensing peptide inhibits tumour-derived exosomes for enhanced cancer immunotherapy
Shin, S., Ko, H., Kim, C. H., Yoon, B. K., Son, S., Lee, J. A., Shin, J. M., Lee, J., Song, S. H., Jackman, J. A., et al. (2023) · Nature Materials · doi:10.1038/s41563-023-01515-2 · Cited by 81
Feng, X., Shen, A., Zhang, W., Jia, S., Iliuk, A. B., Wang, Y., Zhang, W., Zhang, Y., Tao, W. A., & Hu, L. (2024) · Nature Protocols · doi:10.1038/s41596-024-01082-z · Cited by 80
Huang, Y., Kanada, M., Ye, J., Deng, Y., He, Q., Lei, Z., Chen, Y., Li, Y., Qin, P., Zhang, J., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215796 · Cited by 98
Liu, J., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Zheng, H., Fan, Q., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00816-w · Cited by 75
Zhu, M., Chen, C., Foster, N. R., Hartley, C., Mounajjed, T., Salomao, M. A., Fruth, B. F., Beamer, S. E., Kim, Y., Harrington, S. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0413 · Cited by 85
Self-citationExtracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy
Ma, Y., Dong, S., Li, X., Kim, B. Y. S., Yang, Z., & Jiang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.606906 · Cited by 75
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
Gong, N., Zhong, W., Alameh, M., Han, X., Xue, L., El-Mayta, R. D., Zhao, G., Vaughan, A. E., Qin, Z., Xu, F., et al. (2024) · Nature Materials · doi:10.1038/s41563-024-01961-6 · Cited by 85
Engineered exosomes: a promising drug delivery platform with therapeutic potential
Schwarz, G., Ren, X., Xie, W., Guo, H., Jiang, Y. H., & Zhang, J. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1583992 · Cited by 76
Extracellular vesicles and oncogenic signaling
Schubert, A., & Boutros, M. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12855 · Cited by 77
Extracellular vesicles: The key for precision medicine in glioblastoma
Del Bene, M., Osti, D., Faletti, S., Beznoussenko, G. V., DiMeco, F., & Pelicci, G. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noab229 · Cited by 67
Liu, D.-A., Tao, K. X., Wu, B., Yu, Z., Szczepaniak, M., Rames, M. J., Yang, C., Svitkina, T., Zhu, Y., Xu, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42661-0 · Cited by 77
Extracellular vesicles and their role in glioblastoma
Whitehead, C. A., Kaye, A. H., Drummond, K. J., Widodo, S. S., Mantamadiotis, T., Vella, L. J., & Stylli, S. S. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1700208 · Cited by 73
“[100] Serum and Plasma mRNA Huang et al.”
BackgroundChuntova, P., Downey, K., Hegde, B., Almeida, N. D., & Okada, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03062 · Cited by 74
“This effect correlated with the amount of PD-L1 carried by the EVs and was partially reversed through the use of an anti-PD-L1 antibody (113).”
BackgroundEMP3 mediates glioblastoma‐associated macrophage infiltration to drive T cell exclusion
Chen, Q., Jin, J., Huang, X., Wu, F., Huang, H., & Zhan, R. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01954-2 · Cited by 84
Chen, J., Song, Y., Miao, F., Chen, G., Zhu, Y., Wu, N., Pang, L., Chen, Z., & Chen, X. (2021) · Cancer Science · doi:10.1111/cas.15033 · Cited by 76
The Role of Extracellular Vesicles in Metabolic Reprogramming of the Tumor Microenvironment
Fridman, E., Ginini, L., & Gil, Z. (2022) · Cells · doi:10.3390/cells11091433 · Cited by 71
“The negative effect of EV PD-L1 on immunoresponsiveness to tumors has also been demonstrated in melanoma [52], Wilms’ tumor [81], gastric cancer [82], lung cancer [83], and glioblastoma [84], among others.”
BackgroundExtracellular Vesicles as an Advanced Delivery Biomaterial for Precision Cancer Immunotherapy
Ruan, S., Greenberg, Z., Pan, X., Zhuang, P., Erwin, N., & He, M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100650 · Cited by 70
Shin, J. M., Lee, C., Son, S., Kim, C. H., Lee, J. A., Ko, H., Shin, S., Song, S. H., Park, S., Bae, J., et al. (2021) · Advanced Science · doi:10.1002/advs.202103245 · Cited by 68
Totsch, S. K., Schlappi, C., Kang, K., Ishizuka, A. S., Lynn, G. M., Fox, B. M., Beierle, E. A., Whitley, R. J., Markert, J. M., Gillespie, G. Y., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0870-y · Cited by 70
“tion through checkpoint pathway activation [80].”
The Involvement of Exosomes in Glioblastoma Development, Diagnosis, Prognosis, and Treatment
Bălașa, A. F., Şerban, G. M., Chinezu, R., Hurghiș, C., Tămaș, F., & Manu, D. R. (2020) · Brain Sciences · doi:10.3390/brainsci10080553 · Cited by 73
“T cell activity is also reduced by molecules carried by EVs, such as programmed death-ligand 1 (PD-L1), which suppress anti-cancer immunity [49,50].”
BackgroundMechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma
Pang, L., Khan, F., Heimberger, A. B., & Chen, P. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.04.010 · Cited by 67
“Consequently, cancer cell-expressed or EV-delivered ICMs (e.g., PD-L1) suppress T cell function and proliferation by ligating their corresponding receptors on T cells [95,96].”
BackgroundNanoparticle-based biosensors for detection of extracellular vesicles in liquid biopsies
Martín-Gracia, B., Martín‐Barreiro, A., Cuestas-Ayllón, C., Grazú, V., Linē, A., Llorente, A., de la Fuente, J. M., & Moros, M. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00861c · Cited by 68
Fujiwara, Y., Mittra, A., Naqash, A. R., & Takebe, N. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.11 · Cited by 87
“However, PD-L1 has also been detected on the surface of extracellular vesicles (EV) generated from tumor cells, and this EV PD-L1 is associated with the suppression of immunity against tumor and tumor progression([82,83]).”
BackgroundTumor immune escape: extracellular vesicles roles and therapeutics application
Ahmadi, M., Abbasi, R., & Rezaie, J. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01370-3 · Cited by 69
“In addition, circulating EVs of glioblastoma patients contain PD-L1 DNA that is correlated with tumor size [61].”
BackgroundChallenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy
Wang, Y., Zhou, Y., Yang, L., Lei, L., He, B., Cao, J., & Gao, H. (2023) · Advanced Science · doi:10.1002/advs.202303175 · Cited by 84
Spinelli, C., Adnani, L., Choi, D., & Rak, J. W. (2018) · Non-Coding RNA · doi:10.3390/ncrna5010001 · Cited by 69
“This information could potentially reveal, in real time and in a non-invasive manner, several crucial characteristics of the evolving malignancy, such as the molecular subtype, emerging drug targets or therapeutic resistance, immunological status, angiogenic profile, stem cell signals and many other characteristics [9…”
BackgroundHofer, F., Sario, G. D., Musiu, C., Sartoris, S., Sanctis, F. D., & Ugel, S. (2021) · Cells · doi:10.3390/cells10102700 · Cited by 69
“In fact, glioblastoma cells produce EVs containing IDO1, thus suggesting that tumours can exploit both intracellular and extracellular IDO1 to generate an immunosuppressive microenvironment [156].”
BackgroundWu, L., Li, L., Li, S., Liu, L., Xin, W., Li, C., Yin, X., Xu, X., Bao, F., & Hua, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.006 · Cited by 68
Yang, J. A., Chen, J., Liang, H., & Yu, Y. (2022) · Cancer Science · doi:10.1111/cas.15433 · Cited by 71
Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns
Yu, Z., Liu, J., & Chen, G. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00287-3 · Cited by 68
Akbar, S., Raza, A., Mohsin, R., Kanbour, A., Qadri, S. M., Parray, A., Gul, A. R. Z., Philip, A., Vijayakumar, S., Merhi, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1097117 · Cited by 70
“Several studies on various cancers such as glioblastoma, melanoma, and head and neck squamous cell carcinoma (HNSCC) have reported on the role of serum-derived exosomal PD-L1 levels as a potential predictive biomarker for ICIs therapies (12, 47, 48).”
BackgroundTumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors
Zhong, W., Xiao, Z., Qin, Z., Yang, J., Wen, Y., Yu, Z., Li, Y., Sheppard, N. C., Fuchs, S. Y., Xu, X., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2220 · Cited by 66
The Importance of M1-and M2-Polarized Macrophages in Glioma and as Potential Treatment Targets
Ren, J., Xu, B., Ren, J., Liu, Z., Cai, L., Zhang, X., Wang, W., Li, S., Jin, L., & Ding, L. (2023) · Brain Sciences · doi:10.3390/brainsci13091269 · Cited by 69
An emerging interplay between extracellular vesicles and cytokines
Aiello, A., Giannessi, F., Percario, Z. A., & Affabris, E. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.12.003 · Cited by 66
Focus on the morphogenesis, fate and the role in tumor progression of multivesicular bodies
Peng, X., Yang, L., Ma, Y., Li, Y., & Li, H. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00619-5 · Cited by 64
Function of exosomes in neurological disorders and brain tumors
Xiao, L., Hareendran, S., & Loh, Y. P. (2021) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2021.04 · Cited by 77
Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist
Ng, K. W., Attig, J., Young, G. R., Ottina, E., Papamichos, S. I., Kotsianidis, Ι., & Kassiotis, G. (2019) · eLife · doi:10.7554/elife.50256 · Cited by 63
Kim, J., Hong, J., Lee, J., Lahiji, S. F., & Kim, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.002 · Cited by 65
Heuer, S., Burghaus, I., Gose, M., Keßler, T., Sahm, F., Vollmuth, P., Venkataramani, V., Hoffmann, D. C., Schlesner, M., Ratliff, M., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-11846-1 · Cited by 68
“Extracellular vesicles from blood plasma will be evaluated [39].”
Self-citationRicklefs, F. L., Wollmann, K., Salviano‐Silva, A., Drexler, R., Maire, C. L., Kaul, M. G., Reimer, R., Schüller, U., Heinemann, S., Kolbe, K., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae068 · Cited by 65
Self-citationCzystowska, M., & Whiteside, T. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1813276 · Cited by 61
“investigators [43,127,140], which in aggregate indicated that plasma levels of ExoPD-L1 positively correlate with disease stage and progression and that variations in DeltaPD-L1 cor-”
BackgroundTumor-Derived Extracellular Vesicles: Their Role in Immune Cells and Immunotherapy
Li, Q., Cai, S., Li, M., Salma, K. I., Zhou, X., Han, F., Chen, J., & Huyan, T. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s313912 · Cited by 59
Azadi, S., Es, H. A., Bazaz, S. R., Thiery, J. P., Asadnia, M., & Warkiani, M. E. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118526 · Cited by 64
“expressed by activated T cells, leading to bypassing immune checkpoints to evade immune recognition and protects tumor cells from T cell-mediated killing [40].”
BackgroundZheng, Y., Liu, L., Wang, Y., Xiao, S., Mai, R., Zhu, Z., & Cao, Y. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00575-8 · Cited by 58
RetractedExtracellular Vesicles and Their Roles in the Tumor Immune Microenvironment
Reale, A., Khong, T. T., & Spencer, A. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236892 · Cited by 64
Neckles, V. N., Morton, M. C., Holmberg, J. C., Sokolov, A. M., Nottoli, T., Liu, D., & Feliciano, D. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-39679-0 · Cited by 55
The role of exosomal PD-L1 in tumor immunotherapy
Wang, J., Zeng, H., Zhang, H., & Han, Y. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101047 · Cited by 58
Nguyen, L. T. H., Zhang, J., Rima, X. Y., Wang, X., Kwak, K. J., Okimoto, T., Amann, J. M., Yoon, M. J., Shukuya, T., Chiang, C., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12258 · Cited by 62
“…healthy donor EVs, indicative of inflammatory events outside the NSCLC microenvironment consistent with previous investigations (Chen et al., 2018; Ricklefs et al., 2018; Wang et al., 2020), the differences in expression measured by Au SERP demonstrate its potential to diagnose NSCLC. Recent…”
Zhang, M., Fan, Y., Che, X., Hou, K., Zhang, C., Li, C., Wen, T., Wang, S., Cheng, Y., Liu, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00492 · Cited by 57
Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance
Vautrot, V., Bentayeb, H., Causse, S., Garrido, C., & Gobbo, J. (2021) · Cancers · doi:10.3390/cancers13184537 · Cited by 58
“Glioblastoma Plasma; Primary cancer cells lines G34, G35, G44, G157 [61] • Inhibits CD4 + and CD8+ T-cell activation”
BackgroundExtracellular vesicles in glioblastoma: a challenge and an opportunity
Chandran, V. I., Gopala, S., Venkat, E. H., Kjølby, M., & Nejsum, P. L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00600-2 · Cited by 62
Guo, H., Wang, R., Wang, D., Wang, S., Zhou, J., Chai, Z., Yao, S., Li, J., Lu, L., Liu, Y., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.005 · Cited by 53
Non-cytomembrane PD-L1: An atypical target for cancer
Ying, H., Zhang, X., Duan, Y., Lao, M., Xu, J., Yang, H., Liang, T., & Bai, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105741 · Cited by 57
Dou, X., Yan, H., Chen, Z., Chao, F., & Li, M. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac006 · Cited by 55
Tumor-derived nanoseeds condition the soil for metastatic organotropism
Hu, M., Kenific, C. M., Boudreau, N. J., & Lyden, D. C. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.05.003 · Cited by 59
Xia, Y., Wang, W., Shen, W., Xu, K., Hu, Y., Han, G., & Liu, Y.-B. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109652 · Cited by 55
Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy
Ayala‐Mar, S., Donoso‐Quezada, J., & González‐Valdez, J. (2021) · Journal of Immunology Research · doi:10.1155/2021/8839978 · Cited by 55
“As previously mentioned, there is evidence on the presence of PD-L1 mRNA and DNA enclosed in exosomes, as well as small RNA species that regulate the PD-L1 expression in recipient cells [13, 15, 71].”
BackgroundMethodInfluentialAsanuma, K., Nakamura, T., Hayashi, A., Okamoto, T., Iino, T., Asanuma, Y., Hagi, T., Kita, K., Nakamura, K., & Sudo, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-65895-0 · Cited by 53
Asao, T., Tobias, G. C., Lucotti, S., Jones, D. R., Matei, I. R., & Lyden, D. C. (2023) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2023.37 · Cited by 52
“Moreover, cancer-derived EVPs can induce immune suppression by inhibiting T cell activation [55,131,132] , NK cell-mediated cytotoxicity [133] , and promoting the polarization of macrophages towards a tumor-promoting phenotype [134–137] .”
BackgroundMicroparticles from tumors exposed to radiation promote immune evasion in part by PD-L1
Timaner, M., Kotsofruk, R., Raviv, Z., Magidey, K., Shechter, D., Kan, T., Nevelsky, A., Daniel, S., de Vries, E. G. E., Zhang, T., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0971-7 · Cited by 52
Monitoring Therapy Efficiency in Cancer through Extracellular Vesicles
Stevic, I., Buescher, G., & Ricklefs, F. L. (2020) · Cells · doi:10.3390/cells9010130 · Cited by 54
“GBM EVs that were PD-L1high significantly inhibited the magnitude of T cell activation and this was partially reversed by PD1 blockade.”
BackgroundSelf-citationFèvre, C. L., Constans, J., Chambrelant, I., Antoni, D., Bund, C., Leroy‐Freschini, B., Schött, R., Cébula, H., & Noël, G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103230 · Cited by 52
Exosomes as drug delivery systems in glioma immunotherapy
Hao, X., Wang, S., Wang, L., Li, J., Li, Y., & Liu, J. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02611-4 · Cited by 50
“TEXs can disrupt host immunity by inhibiting antigen recognition and presentation by DCs [104], promoting MDSC activation and differentiation [105], inducing the polarization of TAMs toward an immuno-suppressive phenotype [106], and interfering with T cell proliferation and activation [107, 108].”
BackgroundPasini, L., & Ulivi, P. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070998 · Cited by 51
Exosomes in cancer development
Stefanius, K., Servage, K. A., & Orth, K. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.12.018 · Cited by 49
The roles of exosomal immune checkpoint proteins in tumors
Cheng, X., Li, H., Li, R., Yin, L., Zhang, H., Huang, Z., Cheng, Z., Li, J., Wang, Z.-H., & Peng, H. (2021) · Military Medical Research · doi:10.1186/s40779-021-00350-3 · Cited by 59
“A large number of studies on various types of tumors have indicated that it is feasible to dynamically measure the expression of PD-L1 in plasma-derived exosomes, and circulating exosomal PD-L1 is expected to be a potential biomarker of disease progression as well as a prospective predictor of anti-PD-1 therapy [52, 5…”
BackgroundHyung, S., Ko, J., Heo, Y. J., Blum, S. M., Kim, S. T., Park, S. H., Park, J. O., Kang, W. K., Lim, H. Y., Klempner, S. J., et al. (2023) · Science Advances · doi:10.1126/sciadv.adk1098 · Cited by 47
Intercellular transfer of HLA‐G: its potential in cancer immunology
Lin, A., & Yan, W. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1077 · Cited by 52
de Castro, J. V., Gonçalves, C. S., Hormigo, A., & Costa, B. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155278 · Cited by 51
Emerging Role of Exosomes in Retinal Diseases
Zhang, Z., Mugisha, A., Fransisca, S., Liu, Q., Xie, P., & Hu, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.643680 · Cited by 53
Jahan, S., Mukherjee, S., Ali, S., Bhardwaj, U., Choudhary, R. K., Balakrishnan, S., Naseem, A., Mir, S. A., Banawas, S., Alaidarous, M., et al. (2022) · Cells · doi:10.3390/cells11030490 · Cited by 49
Chen, X., Li, J., Zhang, R., Zhang, Y., Wang, X., Leung, E. L., Ma, L., Wong, V. K. W., Liu, L., Neher, E., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12279 · Cited by 50
Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages
Tankov, S., Petrovic, M., Lecoultre, M., Espinoza, F. I., Harane, N. E., Bes, V., Chliate, S., Bedoya, D. M., Jordan, O., Borchard, G., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01523-y · Cited by 50
Imamura, Y., Watanabe, M., Toihata, T., Takamatsu, M., Kawachi, H., Haraguchi, I., Ogata, Y., Yoshida, N., Saeki, H., Oki, E., et al. (2018) · Digestion · doi:10.1159/000494406 · Cited by 46
Morad, G., & Moses, M. A. (2019) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1627164 · Cited by 50
“tional PDL-1 and were able to suppress T cell activation through direct interaction with PD1 [55].”
BackgroundJohnson, A. L., Laterra, J., & López-Bertoni, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.995498 · Cited by 50
The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target
Ye, L., Zhu, Z., Chen, X., Zhang, H., Huang, J., Gu, S., & Zhao, X. (2021) · Cells · doi:10.3390/cells10113247 · Cited by 46
“Researchers have found that the level of exosomal PD-L1 can be used as a possible clinical biomarker to evaluate clinical results, which also reflects the vital role of exosomal PD-L1 [37,38].”
BackgroundResultTi3C2Tx MXene -facilitated non-selective trapping effect: Efficient SERS detection of exosomal PD-L1
Zhou, Y., Chen, Q., Zhong, S., Liu, H., Koh, K., & Chen, H. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115493 · Cited by 44
Immune Escape Mediated by Exosomal PD‐L1 in Cancer
Lawler, S. E., Nowicki, M. O., Ricklefs, F. L., & Chiocca, E. A. (2020) · Advanced Biosystems · doi:10.1002/adbi.202000017 · Cited by 45
Self-citationJin, D., Peng, X., Qin, Y., Wu, P., Lü, H., Wang, L., Huang, J., Li, Y., Zhang, Y., Zhang, G., et al. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c01387 · Cited by 44
Recent Advances on Extracellular Vesicles in Central Nervous System Diseases
Jin, T., Gu, J., Li, Z., Xu, Z., & Gui, Y. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s288415 · Cited by 44
Wang, S., & Gao, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107990 · Cited by 46
Multiplexed RNA profiling by regenerative catalysis enables blood-based subtyping of brain tumors
Zhang, Y., Wong, C. Y., Lim, C. Z. J., Chen, Q., Yu, Z., Natalia, A., Wang, Z., Pang, Q. Y., Lim, S. W., Loh, T. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39844-0 · Cited by 43
Metadata
- Authors
- Ricklefs, F. L., Alayo, Q., Krenzlin, H., Mahmoud, A. B., Speranza, M. C., Nakashima, H., Hayes, J. L., Lee, K., Balaj, L., Passaro, C., Rooj, A. K., Krasemann, S., Carter, B. S., Chen, C. C., Steed, T., Treiber, J., Rodig, S., Yang, K., Nakano, I., Lee, H., Weissleder, R., Breakefield, X. O., Godlewski, J., Westphal, M., Lamszus, K., Freeman, G. J., Bronisz, A., Lawler, S. E., & Chiocca, E. A.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Berkeley (US)
- Massachusetts General Hospital (US)
- University Medical Center Hamburg-Eppendorf (DE)
- University of California San Diego (US)
- Comprehensive Cancer Center, University of Birmingham, Birmingham, AL 35294, USA.
- Harvard University (US)
- Corresponding author
- Lawler, Sean E.
- Chiocca, E. Antonio
- ORCID
- Ricklefs, Franz L.
- Alayo, Quazim
- Krenzlin, Harald
- Mahmoud, Ahmad B.
- Speranza, Maria C.
- Nakashima, Hiroshi
- Hayes, Josie L.
- Lee, Kyungheon
- Balaj, Leonora
- Passaro, Carmela
- Rooj, Arun K.
- Krasemann, Susanne
- Carter, Bob S.
- Chen, Clark C.
- Steed, Tyler
- Treiber, Jeffrey
- Rodig, Scott
- Yang, Katherine
- Nakano, Ichiro
- Lee, Hakho
- Weissleder, Ralph
- Breakefield, Xandra O.
- Godlewski, Jakub
- Westphal, Manfred
- Lamszus, Katrin
- Freeman, Gordon J.
- Bronisz, Agnieszka
- Lawler, Sean E.
- Chiocca, E. Antonio
- Venue
- Science Advances
- Published
- 2018-03-02
- Volume
- 4
- Issue
- 3
- Pages
- eaar2766-eaar2766
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC5842038
- OpenAlex
- W2793992337
- Cited by
- 610
- References
- 42
- Citations by year
- 2026: 48 · 2025: 68 · 2024: 76 · 2023: 76 · 2022: 85 · 2021: 111 · 2020: 75 · 2019: 56 · 2018: 15
- FWCI
- 22.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Science Advances (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (CA176203-01A1)
- National Cancer Institute (P01 CA69246)
- Deutsche Forschungsgemeinschaft (RI 2616/1-1, RI 2616/2-1)
- National Institute of Health (NCI P01 CA69246)
- American-Italian Cancer Foundation Post-doctoral Research Fellowship
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- glioblastoma, PD-L1, extracellular vesicles, immune evasion, antitumor immunity, tumor microenvironment, biomarkers
- MeSH terms
- Extracellular Vesicles, Antigens, Neoplasm, Brain Neoplasms, Glioblastoma, Humans, Interferon-gamma, Lymphocyte Activation, Receptors, Antigen, T-Cell, T-Lymphocytes, Neoplastic Stem Cells, Up-Regulation, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Immune Evasion, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.